Boc-Tyr-NHMe

• 分子结构分类: 有机化合物 - 有机酸及其衍生物 - 羧酸及其衍生物
• 英文名称: Boc-Tyr-NHMe
• 英文别名: tert-butyl (S)-(3-(4-hydroxyphenyl)-1-(methylamino)-1-oxopropan-2-yl)carbamate；Nα-(tert-butoxycarbonyl)-L-tyrosine N-methylamide；Nalpha-(tert-butoxycarbonyl)-L-tyrosine N-methylamide；tert-butyl N-[(2S)-3-(4-hydroxyphenyl)-1-(methylamino)-1-oxopropan-2-yl]carbamate
• 化学式: C₁₅H₂₂N₂O₄
• 分子量: 294.351
• InChiKey: RCAGVZXOXDJSNK-LBPRGKRZSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  1.1
• 重原子数：
  21
• 可旋转键数：
  6
• 环数：
  1.0
• sp3杂化的碳原子比例：
  0.47
• 拓扑面积：
  87.7
• 氢给体数：
  3
• 氢受体数：
  4

反应信息

• 作为反应物：
  描述：

  Boc-Tyr-NHMe 在 盐酸 、 1-羟基苯并三唑 、 盐酸-N-乙基-Nˊ-(3-二甲氨基丙基)碳二亚胺 、 三氟乙酸 作用下， 以 乙酸乙酯 、 N,N-二甲基甲酰胺 为溶剂， 反应 3.0h， 生成 (2S,3R)-3-[(S)-2-(4-Hydroxy-phenyl)-1-methylcarbamoyl-ethylcarbamoyl]-5-methyl-2-(3-phenyl-propyl)-hexanoic acid
  参考文献：
  名称：

  Highly water-soluble matrix metalloproteinases inhibitors and their effects in a rat adjuvant-induced arthritis model

  摘要：

  A new series of succinate-based dual inhibitors against matrix metalloproteinases (MMPs) and tumor necrosis factor or. converting enzyme (TACE) possessing highly-water solubility was designed, synthesized, and evaluated for enzyme inhibition. Incorporating of acidic or basic functional groups at the P-2' position afforded sufficient water solubility without significant loss of inhibitory potencies. Compound 18e, which had a guanidino group at the P-2' position as the basic functional group, exhibited broad inhibition against target enzymes for a relatively long period in rat plasma (beta1(1/2): 2.0 h) after sc administration when compared with compounds possessing acidic functional groups (18a and 18b). Consequently, the representative compound 18e together with compound 18b. Marimastat and Trocade were evaluated in the rat adjuvant-induced arthritis model, a model of chronic cartilage destruction. It is concluded that the newly synthesized highly water-soluble compound 18e showed significant activity in suppressing hindpaw swelling and the bone destruction with a minimal administration period (days 3-7). (C) 2002 Elsevier Science Ltd. All rights reserved.

  DOI：

  10.1016/s0968-0896(02)00109-8
• 作为产物：
  描述：

  L-酪氨酸 在 4-二甲氨基吡啶 、 盐酸-N-乙基-Nˊ-(3-二甲氨基丙基)碳二亚胺 、 N,N-二异丙基乙胺 、 sodium hydroxide 作用下， 以 1,4-二氧六环 、 水 、 N,N-二甲基甲酰胺 为溶剂， 生成 Boc-Tyr-NHMe
  参考文献：
  名称：

  使用双氰基芳烃光诱导电子转移促进苯丙氨酸和酪氨酸衍生物的脱苄基作用

  摘要：

  苯丙氨酸和酪氨酸衍生物与双氰基芳烃的光诱导脱苄基反应通过产生自由基阳离子提供了甘氨酸衍生物。尽管底物范围有限，但在N端带有氨基甲酸酯（无芳族基团）和C端带有酰胺的苯丙氨酸和酪氨酸衍生物的自由基阳离子可通过以下方式促进苄基位置的C–C键断裂：光诱导的电子转移。重要的是要了解涉及电子转移的酶中苯丙氨酸和酪氨酸的自由基阳离子的化学行为。

  DOI：

  10.1016/j.tet.2017.11.021

文献信息

• Sulfonic acid derivatives of hydroxamic acids and their use as medicinal products
  申请人：——

  公开号：US20030176486A1

  公开（公告）日：2003-09-18

  The present invention relates to a novel sulfonic acid derivative of hydroxamic acid or a pharmacologically acceptable salt thereof. More particularly, the present invention relates to a sulfonic acid derivative of hydroxamic acid or a pharmacologically acceptable salt thereof, which is useful as an inhibitor of lipopolysaccharides (LPS). In addition, the present invention relates to a novel intermediate compound useful for the synthesis of this sulfonic acid derivative of hydroxamic acid.

  本发明涉及羟羰酸的新型磺酸衍生物或其药理学上可接受的盐。更具体地，本发明涉及一种羟羰酸的磺酸衍生物或其药理学上可接受的盐，其用作脂多糖（LPS）的抑制剂。此外，本发明涉及一种新型中间化合物，用于合成这种羟羰酸的磺酸衍生物。
• Novel [1,2,4]Triazolo[4,3-a]Quinoxaline Derivative, Method For Preparing Same, And Pharmaceutical Composition For Preventing Or Treating BET Protein-Related Diseases, Containing Same As Active Ingredient
  申请人：Dong Wha Pharm. Co., Ltd.

  公开号：US20200039984A1

  公开（公告）日：2020-02-06

  Provided are a novel [1,2,4]triazolo[4,3-a]quinoxaline derivative, a method for preparing the same, and a pharmaceutical composition for preventing or treating bromodomain extra-terminal (BET) protein-related diseases including cancer and autoimmune diseases, containing the same as an active ingredient.

  提供了一种新型[1,2,4]三唑并[4,3-a]喹喔啉衍生物，一种制备该衍生物的方法，以及一种用于预防或治疗与溴结构域额外末端（BET）蛋白相关的疾病，包括癌症和自身免疫疾病的药物组合物，其中该衍生物作为活性成分。
• [EN] MACROCYCLIC INHIBITORS OF MATRIX METALLOPROTEINASES AND TNF alpha SECRETION<br/>[FR] INHIBITEURS MACROCYCLIQUES DE METALLOPROTEINASES MATRICIELLES ET DE SECRETION DE FNT alpha
  申请人：ABBOTT LABORATORIES

  公开号：WO1998030551A1

  公开（公告）日：1998-07-16

  (EN) Macrocyclic compounds of formula (I) are potent inhibitors of matrix metalloproteinase and are useful in the treatment of diseases in which matrix metalloproteinase play a role. Also disclosed are matrix metalloproteinase inhibiting compositions and a method of inhibiting matrix metalloproteinase in a mammal.(FR) Cette invention concerne des composés macrocycliques qui correspondent à la formule (I). Ces composés consistent en de puissants inhibiteurs de métalloprotéinase matricielle, et peuvent être utilisés dans le traitement de maladies où la métalloprotéinase matricielle joue un rôle. Cette invention concerne également des compositions inhibant la métalloprotéinase matricielle, ainsi qu'un procédé d'inhibition de métalloprotéinase matricielle chez un mammifère.

  (中) 公式（I）的大环化合物是基质金属蛋白酶的有效抑制剂，可用于治疗基质金属蛋白酶发挥作用的疾病。还揭示了抑制基质金属蛋白酶的组合物和在哺乳动物中抑制基质金属蛋白酶的方法。
• SULFONIC ACID DERIVATIVES OF HYDROXAMIC ACIDS AND THEIR USE AS MEDICINAL PRODUCTS
  申请人：Welfide Corporation

  公开号：EP1306367A1

  公开（公告）日：2003-05-02

  The present invention relates to a novel sulfonic acid derivative of hydroxamic acid or a pharmacologically acceptable salt thereof. More particularly, the present invention relates to a sulfonic acid derivative of hydroxamic acid or a pharmacologically acceptable salt thereof, which is useful as an inhibitor of lipopolysaccharides (LPS). In addition, the present invention relates to a novel intermediate compound useful for the synthesis of this sulfonic acid derivative of hydroxamic acid.

  本发明涉及一种新型羟肟酸磺酸衍生物或其药理学上可接受的盐。更具体地说，本发明涉及一种羟肟酸的磺酸衍生物或其药理学上可接受的盐，可用作脂多糖（LPS）的抑制剂。此外，本发明还涉及一种可用于合成羟肟酸磺酸衍生物的新型中间体化合物。
• [1,2,4]Triazolo[4,3-a]quinoxaline derivative, method for preparing same, and pharmaceutical composition for preventing or treating BET protein-related diseases, containing same as active ingredient
  申请人：Dong Wha Pharm. Co., Ltd.

  公开号：US11028090B2

  公开（公告）日：2021-06-08

  Provided are a novel [1,2,4]triazolo[4,3-a]quinoxaline derivative, a method for preparing the same, and a pharmaceutical composition for preventing or treating bromodomain extra-terminal (BET) protein-related diseases including cancer and autoimmune diseases, containing the same as an active ingredient.

  本文提供了一种新颖的[1,2,4]三唑并[4,3-a]喹喔啉衍生物、一种制备方法和一种药物组合物，用于预防或治疗包括癌症和自身免疫性疾病在内的溴代端外蛋白（BET）相关疾病。